


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior listings of claims in the application:

1. (CURRENTLY AMENDED) A composition comprising a pharmaceutically acceptable formulation of formula 1



Formula 1

wherein

R<sub>3</sub> is C<sub>1</sub>-C<sub>10</sub> alkyl;

R<sub>4</sub> to R<sub>7</sub> are independently selected from the group consisting of -H, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>1</sub>-C<sub>10</sub> polyalkoxyalkyl, C<sub>1</sub>-C<sub>20</sub> polyhydroxyalkyl, C<sub>5</sub>-C<sub>20</sub> polyhydroxyaryl, saccharides, amino, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> aryl, -SO<sub>3</sub>T, -CO<sub>2</sub>T, -OH, -(CH<sub>2</sub>)<sub>a</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>OSO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHOSO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>OCO(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>CONH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHCO(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHCONH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHCSNH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>OCONH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>OPO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>OPO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>NHPO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>NHPO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>OCO(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>OCO(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>CONH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>CONH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>NHCO(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>NHCO(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>NHCONH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>NHCONH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>NHCSNH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>NHCSNH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>OCONH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>OCONH(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -CH<sub>2</sub>(CH<sub>2</sub>-O-CH<sub>2</sub>)-CH<sub>2</sub>-OH, -(CH<sub>2</sub>)<sub>a</sub>-CO<sub>2</sub>T, -CH<sub>2</sub>(CH<sub>2</sub>-O-CH<sub>2</sub>)-CH<sub>2</sub>-CO<sub>2</sub>T, -(CH<sub>2</sub>)<sub>a</sub>-NH<sub>2</sub>, -CH<sub>2</sub>(CH<sub>2</sub>-O-CH<sub>2</sub>)<sub>g</sub>-CH<sub>2</sub>-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>b</sub>-N(R<sub>a</sub>)-(CH<sub>2</sub>)<sub>c</sub>-CO<sub>2</sub>T, and -(CH<sub>2</sub>)<sub>j</sub>-N(R<sub>b</sub>)-CH<sub>2</sub>-(CH<sub>2</sub>-O-CH<sub>2</sub>)<sub>k</sub>-CH<sub>2</sub>-CO<sub>2</sub>T;

Y<sub>1</sub> is selected from the group consisting of C<sub>5</sub>-C<sub>20</sub> polyhydroxyaryl, saccharides, hydrophilic peptides, arylpolysulfonates, -(CH<sub>2</sub>)<sub>a</sub>OSO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHOSO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>OCO(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>CONH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHCO(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHCONH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>NHCSNH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>OCONH(CH<sub>2</sub>)<sub>b</sub>SO<sub>3</sub>T, -(CH<sub>2</sub>)<sub>a</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>OPO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>OPO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>NHPO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>NHPO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT, -(CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>T<sub>2</sub>, -(CH<sub>2</sub>)<sub>a</sub>OCO(CH<sub>2</sub>)<sub>b</sub>PO<sub>3</sub>HT,

$-(CH_2)_aOCO(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aCONH(CH_2)_bPO_3HT$ ,  $-(CH_2)_aCONH(CH_2)_bPO_3T_2$ ,  
 $-(CH_2)_aNHCO(CH_2)_bPO_3HT$ ,  $-(CH_2)_aNHCO(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aNHCONH(CH_2)_bPO_3HT$ ,  
 $-(CH_2)_aNHCONH(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aNHCSNH(CH_2)_bPO_3HT$ ,  $-(CH_2)_aNHCSNH(CH_2)_bPO_3T_2$ ,  
 $-(CH_2)_aOCONH(CH_2)_bPO_3HT$ ,  $-(CH_2)_aOCONH(CH_2)_bPO_3T_2$ ,  $-CH_2(CH_2)_cO-CH_2-CH_2-OH$ , and  
 $-(CH_2)_n-N(R_a)-(CH_2)_m-CO_2T$ ;  $-(CH_2)_h-N(R_a)-(CH_2)_i-CO_2^-$

$W_1$  is  $-CR_cR_d$ ;

$a, b, d, f, h, i$ , and  $j$  independently vary from 1-10;


$c, e, g$ , and  $k$  independently vary from 1-100;

$R_a, R_b, R_c$ , and  $R_d$  are defined in the same manner as  $Y_1$ ; and

$T$  is either H or a negative charge.

## 2-3. (CANCELED)

4. (WITHDRAWN) A method for performing a diagnostic procedure which comprises administering to an individual an effective amount of a composition comprising formula 1



Formula 1

wherein  $R_3$  to  $R_7$ , and  $Y_1$  are independently selected from the group consisting of  $-H$ , C1-C10  
 alkoxy, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, saccharides,  
 amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C6-  
 C10 alkyl, C1-C10 aryl,  $-SO_3T$ ,  $-CO_2T$ ,  $-OH$ ,  $-(CH_2)_aSO_3T$ ,  $-(CH_2)_aOSO_3T$ ,  $-(CH_2)_aNHOSO_3T$ ,  
 $-(CH_2)_aCO_2(CH_2)_bSO_3T$ ,  $-(CH_2)_aOCO(CH_2)_bSO_3T$ ,  $-(CH_2)_aCONH(CH_2)_bSO_3T$ ,  
 $-(CH_2)_aNHCO(CH_2)_bSO_3T$ ,  $-(CH_2)_aNHCONH(CH_2)_bSO_3T$ ,  $-(CH_2)_aNHCSNH(CH_2)_bSO_3T$ ,  
 $-(CH_2)_aOCONH(CH_2)_bSO_3T$ ,  $-(CH_2)_aPO_3HT$ ,  $-(CH_2)_aPO_3T_2$ ,  $-(CH_2)_aOPO_3HT$ ,  $-(CH_2)_aOPO_3T_2$ ,  
 $-(CH_2)_aNHPO_3HT$ ,  $-(CH_2)_aNHPO_3T_2$ ,  $-(CH_2)_aCO_2(CH_2)_bPO_3HT$ ,  $-(CH_2)_aCO_2(CH_2)_bPO_3T_2$ ,  
 $-(CH_2)_aOCO(CH_2)_bPO_3HT$ ,  $-(CH_2)_aOCO(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aCONH(CH_2)_bPO_3HT$ ,  
 $-(CH_2)_aCONH(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aNHCO(CH_2)_bPO_3HT$ ,  $-(CH_2)_aNHCO(CH_2)_bPO_3T_2$ ,  
 $-(CH_2)_aNHCONH(CH_2)_bPO_3HT$ ,  $-(CH_2)_aNHCONH(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aNHCSNH(CH_2)_bPO_3HT$ ,

$-(CH_2)_aNHCSNH(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aOCONH(CH_2)_bPO_3HT$ , and  $-(CH_2)_aOCONH(CH_2)_bPO_3T_2$ ,  $-CH_2(CH_2-O-CH_2)_c-CH_2-OH$ ,  $-(CH_2)_d-CO_2T$ ,  $-CH_2-(CH_2-O-CH_2)_e-CH_2-CO_2T$ ,  $-(CH_2)_f-NH_2$ ,  $-CH_2-(CH_2-O-CH_2)_g-CH_2-NH_2$ ,  $-(CH_2)_h-N(R_a)-(CH_2)_i-CO_2T$ , and  $-(CH_2)_j-N(R_b)-CH_2-(CH_2-O-CH_2)_k-CH_2-CO_2T$ ;  $W_1$  is selected from the group consisting of  $-CR_cR_d$ ,  $-O-$ , and  $-NR_c$ ;  $a$ ,  $b$ ,  $d$ ,  $f$ ,  $h$ ,  $i$ , and  $j$  independently vary from 1-10;  $c$ ,  $e$ ,  $g$ , and  $k$  independently vary from 1-100;  $R_a$ ,  $R_b$ ,  $R_c$ , and  $R_d$  are defined in the same manner as  $Y_1$ ;  $T$  is either H or a negative charge.

5. (WITHDRAWN) The method for performing the diagnostic or therapeutic procedure of claim 4 which comprises administering to an individual an effective amount of the composition wherein  $R_3$  to  $R_7$ , and  $Y_1$  are independently selected from the group consisting of C1-C5 alkoxy, C1-C5 polyalkoxyalkyl, C1-C10 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, mono- and disaccharides, nitro, hydrophilic peptides, arylpolysulfonates, C1-C10 aryl,  $-SO_3T$ ,  $-CO_2T$ ,  $-OH$ ,  $-(CH_2)_aSO_3T$ ,  $-(CH_2)_bOSO_3T$ ,  $-(CH_2)_cNHOSO_3T$ ,  $-(CH_2)_dCO_2(CH_2)_eSO_3T$ ,  $-(CH_2)_fOCO(CH_2)_gSO_3T$ ,  $-CH_2(CH_2-O-CH_2)_c-CH_2-OH$ ,  $-(CH_2)_d-CO_2T$ ,  $-CH_2-(CH_2-O-CH_2)_e-CH_2-CO_2T$ ,  $-(CH_2)_f-NH_2$ ,  $-CH_2-(CH_2-O-CH_2)_g-CH_2-NH_2$ ,  $-(CH_2)_h-N(R_a)-(CH_2)_i-CO_2T$ , and  $-(CH_2)_j-N(R_b)-CH_2-(CH_2-O-CH_2)_k-CH_2-CO_2T$ ;  $W_1$  is selected from the group consisting of  $-CR_cR_d$ ,  $-O-$ , and  $-NR_c$ ;  $a$ ,  $b$ ,  $d$ ,  $f$ ,  $h$ ,  $i$ , and  $j$  independently vary from 1-5;  $c$ ,  $e$ ,  $g$ , and  $k$  independently vary from 1-20;  $R_a$ ,  $R_b$ ,  $R_c$ , and  $R_d$  are defined in the same manner as  $Y_1$ ;  $T$  is a negative charge.

6. (WITHDRAWN) The method for performing the diagnostic or therapeutic procedure of claim 5 which comprises administering to an individual an effective amount of the composition wherein each  $R_3$ ,  $R_4$ ,  $R_6$  and  $R_7$  is H,  $R_5$  is  $SO_3T$ ,  $Y_1$  is  $-(CH_2)_3SO_3T$ ;  $W_1$  is  $-C(CH_3)_2$ ;  $T$  is a negative charge.


7. (WITHDRAWN) The method of claim 4 wherein said procedure utilizes light of wavelength in the region of 350-1300 nm.

8. (WITHDRAWN) The method of claim 4 wherein said diagnostic procedure comprises monitoring a blood clearance profile by fluorescence wherein light of wavelength in the region of 350 to 1300 nm is utilized.

9. (WITHDRAWN) The method of claim 4 wherein said diagnostic procedure comprises monitoring a blood clearance profile by absorption wherein light of wavelength in the region of 350 to 1300 nm is utilized.

10. (WITHDRAWN) The method of claim 4 wherein said procedure is for physiological function monitoring.

11. (WITHDRAWN) The method of claim 10 wherein the diagnostic procedure is for renal function monitoring.
12. (WITHDRAWN) The method of claim 10 wherein the diagnostic procedure is for cardiac function monitoring.
13. (WITHDRAWN) The method of claim 10 wherein the diagnostic procedure is for kidney function monitoring.
14. (WITHDRAWN) The method of claim 10 wherein the diagnostic procedure is for determining organ perfusion in vivo.
15. (CANCELED)
16. (WITHDRAWN) A method for performing a diagnostic procedure which comprises administering to an individual an effective amount of formula 1



Formula 1

wherein  $R_3$  to  $R_7$ , and  $Y_1$  are independently selected from the group consisting of -H, C1-C10 alkoxy, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, saccharides, amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C6-C10 alkyl, C1-C10 aryl,  $-\text{SO}_3\text{T}$ ,  $-\text{CO}_2\text{T}$ ,  $-\text{OH}$ ,  $-(\text{CH}_2)_a\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{OSO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{NHSO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{CO}_2(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{OCO}(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{CONH}(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{NHCO}(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{NHCONH}(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{NHCSNH}(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{OCONH}(\text{CH}_2)_b\text{SO}_3\text{T}$ ,  $-(\text{CH}_2)_a\text{PO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{PO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{OPO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{OPO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{NHPO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{NHPO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{CO}_2(\text{CH}_2)_b\text{PO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{CO}_2(\text{CH}_2)_b\text{PO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{OCO}(\text{CH}_2)_b\text{PO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{OCO}(\text{CH}_2)_b\text{PO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{CONH}(\text{CH}_2)_b\text{PO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{CONH}(\text{CH}_2)_b\text{PO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{NHCO}(\text{CH}_2)_b\text{PO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{NHCO}(\text{CH}_2)_b\text{PO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{NHCONH}(\text{CH}_2)_b\text{PO}_3\text{HT}$ ,  $-(\text{CH}_2)_a\text{NHCONH}(\text{CH}_2)_b\text{PO}_3\text{T}_2$ ,  $-(\text{CH}_2)_a\text{NHCSNH}(\text{CH}_2)_b\text{PO}_3\text{HT}$ ,

$-(CH_2)_aNHCSNH(CH_2)_bPO_3T_2$ ,  $-(CH_2)_aOCONH(CH_2)_bPO_3HT$ , and  $-(CH_2)_aOCONH(CH_2)_bPO_3T_2$ ,  
 $-CH_2(CH_2-O-CH_2)_c-CH_2-OH$ ,  $-(CH_2)_d-CO_2T$ ,  $-CH_2-(CH_2-O-CH_2)_e-CH_2-CO_2T$ ,  $-(CH_2)_f-NH_2$ ,  $-CH_2-$   
 $(CH_2-O-CH_2)_g-CH_2-NH_2$ ,  $-(CH_2)_h-N(R_a)-(CH_2)_i-CO_2T$ , and  $-(CH_2)_j-N(R_b)-CH_2-(CH_2-O-CH_2)_k-CH_2-$   
 $CO_2T$ ;  $W_1$  is selected from the group consisting of  $-CR_cR_d$ ,  $-O-$ ,  $-NR_c$ , and  $-S-$ ;  $a$ ,  $b$ ,  $d$ ,  $f$ ,  $h$ ,  $i$ , and  $j$   
independently vary from 1-10;  $c$ ,  $e$ ,  $g$ , and  $k$  independently vary from 1-100;  $R_a$ ,  $R_b$ ,  $R_c$ , and  $R_d$   
are defined in the same manner as  $Y_1$ ;  $T$  is either H or a negative charge; with the proviso that  
when  $W_1$  is  $-S-$ ,  $R_3-R_7$  are not  $-H$  or C1-C10 alkyl; and  $Y_1$  is not  $-H$ .

17. (PREVIOUSLY PRESENTED) The composition of claim 1 wherein  $R_3$  is  $C_1$  alkyl.

18. CANCELED

19. (PREVIOUSLY PRESENTED) The composition of claim 17 wherein each of  $R_4$  to  $R_7$  is independently  $-H$  or  $-SO_3T$ .

20-22. CANCELED

23. (PREVIOUSLY PRESENTED) The composition of claim 1 wherein each of  $R_4$  to  $R_7$  is independently  $-H$  or  $-SO_3T$ .

24-26. CANCELED